Nephrostomy Devices Market By Product Type (Nephrostomy Catheters, Guidewires, Drainage Bags, Access Needles, Sheaths and Dilators, Other Products); By Application (Kidney Stones, Hydronephrosis, Kidney Cancer, Postoperative Urinary Diversion, Injury-Induced Obstruction); By End User (Hospitals, Ambulatory Surgical Centres, Specialty Clinics, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Nephrostomy Devices Market: Repeat Procedures, Hospital Contracts and Portfolio Control Shape Commercial Growth

The Global Nephrostomy Devices Market was valued at USD 1.00 billion in 2025 and is projected to reach USD 1.60 billion by 2032, growing at a CAGR of 6.9%, according to Strategic Market Research.

 

FDA-approved nephrostomy devices include pigtail, balloon, and Malecot drainage catheters, supplied by major manufacturers such as Boston Scientific and Cook Medical under FDA device codes including GBO and LJE. Pigtail catheters are the most widely used because their curled tips help maintain secure placement, with examples including Boston Scientific’s Flexima and Percuflex product lines. Balloon-based systems, such as Cook Medical’s X-Force catheter, combine tract dilation and drainage in a single step to improve procedural efficiency, while Malecot catheters use a winged-tip design and are generally selected for short-term or specialized drainage. Procedural kits containing guidewires, dilators, and puncture needles also remain essential for safe renal access and are frequently bundled with catheters in hospital purchasing.

 

Product innovation is increasingly focused on improving patient comfort, maintaining drainage efficiency, and reducing blockage, infection, and accidental tube dislodgement across hospitals, outpatient facilities, and home-care settings. Securement systems such as Nephro-Safe™, developed through TubeX/Cathetrix, use anti-slide technology and a dual-layer adhesive mechanism to absorb body movements and limit external traction on the tube. Low-profile catheters with flexible shafts further reduce discomfort and internal renal irritation, while silicone balloon catheters such as Nefroquick incorporate an integrated retention balloon and reinforced safety tip to support stable placement and effective drainage from the renal pelvis and calyces.

 

Antimicrobial coatings help limit bacterial attachment and colonization, potentially lowering the risk of catheter-associated urinary tract infections during prolonged use. High-purity biocompatible silicone and other incrustation-resistant materials reduce mineral accumulation, preserve catheter function, and may extend safe dwell times. Miniaturized devices such as Argon Medical’s Skater mini-loop catheter use anchor loops up to 40% smaller than conventional designs, allowing secure drainage of smaller fluid cavities with less discomfort. Portable micro-ultrasound systems compatible with mobile devices, together with three-dimensional CT reconstruction and tracking, also support more accurate renal access, improved catheter placement, and fewer procedure-related complications.

 

Growing Demand for Nephrostomy Tube Securement Technologies

Demand for advanced nephrostomy tube securement solutions is increasing as hospitals and home-care providers focus on reducing accidental dislodgement, repeat interventions, infection risk, and the overall cost of nephrostomy management. External pulling, routine body movement, and inadequate fixation can interrupt drainage and lead to emergency catheter replacement, additional imaging, longer hospital stays, and greater patient discomfort. The absence of standardized securement practices for nephrostomy and other drainage catheters has also created a market opportunity for dedicated stabilization products that offer greater reliability than conventional tapes and sutures.

Manufacturers are responding by developing nephrostomy-specific systems designed for both institutional and long-term home-care use. The planned launch of Nephro-Safe by TubeX and Cathetrix at MEDICA 2025 reflects growing commercial interest in anti-pull technologies that improve tube stability while supporting patient comfort and mobility. Its adhesive anchoring and movement-absorbing design address the need to prevent traction from reaching the insertion site. With millions of patients relying on urinary drainage catheters, increasing long-term catheter use, greater emphasis on avoiding preventable readmissions, and rising adoption of home-based care are expected to drive demand for advanced nephrostomy securement devices.

 

Stone Disease Supports Complex Procedure Volumes

Global Burden of Disease estimates identified approximately 106 million incident urolithiasis cases worldwide and 4.23 million in the United States in 2021. Global incident cases increased by 26.7% between 2000 and 2021.

Most stone patients do not require nephrostomy. External drainage is concentrated among patients with infected obstruction, anuria, severe hydronephrosis, threatened kidney function, difficult anatomy or large stones requiring percutaneous access. Commercial forecasting should therefore track complicated stone episodes rather than apply a nephrostomy penetration rate to the entire stone population.

Urolithiasis was associated with an estimated 17,700 deaths globally and 921 deaths in the United States in 2021. These deaths are concentrated in severe disease, particularly where obstruction is complicated by infection, sepsis or kidney injury. Hospitals treating large emergency stone populations have a stronger requirement for ready-to-use drainage kits and continuous interventional-radiology coverage.

Percutaneous nephrolithotomy also supports demand for needles, wires, dilators, sheaths and access sets. A U.S. claims study covering 8,348 patients found that the outpatient share of initial PCNL procedures increased from 40.1% in 2010 to 85.3% in 2019. Purchasing has consequently expanded from inpatient operating rooms to hospital outpatient departments and specialist stone centres.

Tubeless PCNL reduces routine postoperative catheter use in uncomplicated cases, but every PCNL procedure still requires renal access. Revenue is shifting from standard postoperative tubes toward access kits and selected drainage products used in complex procedures.

 

Malignant Obstruction Produces Higher Use per Patient

A U.S. inpatient analysis identified approximately 238,500 malignant extrinsic ureteral-obstruction cases between 2010 and 2015. Nephrostomy was used in 11.4% of cases, equivalent to approximately 27,189 inpatient events over six years or 4,532 annually for this indication.

The figure excludes outpatient placements, scheduled exchanges, bilateral drainage and unplanned replacements. Cancer-related obstruction can require several devices during one treatment period, giving oncology accounts a higher consumption rate than their patient numbers suggest.

Renal decompression may preserve sufficient kidney function for selected patients to begin or continue chemotherapy, radiotherapy or other oncology care. Hospitals treating advanced pelvic and genitourinary cancers therefore value reliable drainage and predictable exchange schedules because catheter complications can interrupt wider cancer treatment.

Internal stents remain suitable for many patients, but severe tumour compression can prevent successful placement. Failed stenting, recurrent obstruction and difficult anatomy preserve a recurring nephrostomy pathway in oncology care.

 

Product Type Segment Analysis

Nephrostomy catheters account for an estimated 40.0% of global revenue in 2025, equal to USD 400.0 million. The segment is projected to reach USD 621.6 million by 2032 at a CAGR of 6.5%. Catheters remain the largest product category because they are required during initial drainage and every subsequent exchange. Their share is expected to decline modestly to 38.8% by 2032 as accessories and renal-access products grow faster.

Guidewires represent 14.0% of the market in 2025, equivalent to USD 140.0 million. Revenue is forecast to reach USD 224.8 million by 2032 at a CAGR of 7.0%. Guidewires are used in initial placement, catheter exchange, nephroureteral conversion and antegrade intervention. Hospitals increasingly standardize wires with compatible needles, dilators and catheters, allowing suppliers to secure broader procedural contracts.

Drainage bags account for 13.0% of 2025 revenue, or USD 130.0 million. The segment records the highest product CAGR at 7.8% and is projected to reach USD 219.9 million by 2032. Growth reflects repeated replacement during prolonged external drainage. Cancer patients and individuals with non-correctable obstruction may use several bags during one catheter cycle, raising accessory revenue without requiring another placement.

Access needles hold an estimated 10.0% share, equal to USD 100.0 million in 2025. Revenue is projected to reach USD 153.4 million by 2032 at a CAGR of 6.3%. Demand is linked mainly to new placements and PCNL access, giving the category less recurring use than catheters or bags.

Sheaths and dilators represent 14.0% of the market in 2025, or USD 140.0 million. The segment is forecast to reach USD 230.8 million by 2032 at a CAGR of 7.4%. PCNL growth, outpatient renal-access procedures and greater use of complete kits support expansion. Tubeless surgery can reduce postoperative tube placement, but it does not remove the need for tract dilation and percutaneous access.

Other products, including fixation devices, connectors, stopcocks, dressings and replacement accessories, account for 9.0% of revenue in 2025, equal to USD 90.0 million. The category is projected to reach USD 149.5 million by 2032 at a CAGR of 7.5%. Repeated use during catheter maintenance gives these products a higher growth rate than access needles and primary catheters.

 

Application Segment Analysis

Kidney stones represent the largest application with an estimated 32.0% share in 2025, equivalent to USD 320.0 million. Revenue is forecast to reach USD 507.2 million by 2032 at a CAGR of 6.8%. Growth comes from infected obstruction, severe hydronephrosis, PCNL access and failed-stent cases rather than the total stone population.

Hydronephrosis accounts for 30.0% of market revenue in 2025, equal to USD 300.0 million. The segment is projected to reach USD 484.9 million by 2032 at a CAGR of 7.1%. Within this segmentation, hydronephrosis covers non-stone and non-cancer obstruction to prevent overlap with the other application categories. Nephrostomy use rises when renal dilation threatens kidney function or when retrograde drainage is not possible.

Kidney cancer holds an estimated 17.0% share, representing USD 170.0 million in 2025. Revenue is projected to reach USD 284.3 million by 2032 at a CAGR of 7.6%, the fastest rate among the application segments. Longer catheter duration, bilateral obstruction and repeated exchanges increase device consumption per patient. Oncology hospitals also require dependable drainage to prevent treatment delays caused by renal dysfunction.

Postoperative urinary diversion represents 12.0% of the market in 2025, equal to USD 120.0 million. Revenue is forecast to reach USD 186.5 million by 2032 at a CAGR of 6.5%. Pelvic surgery, urinary reconstruction, transplantation and treatment of ureteral leaks can require temporary diversion while tissue heals. Shorter catheter duration keeps growth below the cancer and hydronephrosis segments.

Injury-induced obstruction accounts for 9.0% of 2025 revenue, or USD 90.0 million. The segment is projected to reach USD 137.1 million by 2032 at a CAGR of 6.2%. Demand is concentrated in tertiary hospitals with trauma, transplant, gynecologic and complex pelvic-surgery services. Lower and less predictable case volumes limit the segment’s overall contribution.

 

End-User Segment Analysis

Hospitals account for 74.0% of global market revenue in 2025, equivalent to USD 740.0 million. The segment is projected to reach USD 1.16 billion by 2032 at a CAGR of 6.7%. Emergency decompression, malignant obstruction and complex PCNL procedures require imaging, anesthesia support, interventional radiology and inpatient backup, keeping hospitals dominant.

Ambulatory surgical centres represent 13.0% of the market in 2025, or USD 130.0 million. Revenue is forecast to reach USD 228.6 million by 2032 at a CAGR of 8.4%, the fastest rate among end users. Growth is concentrated in planned exchanges, selected stone procedures and lower-risk percutaneous interventions. Emergency infected-obstruction cases will remain hospital based.

Specialty clinics account for 10.0% of market revenue, equal to USD 100.0 million in 2025. The segment is projected to reach USD 163.8 million by 2032 at a CAGR of 7.3%. Urology and interventional clinics participate in catheter maintenance, bag replacement, follow-up and selected exchange procedures. Their revenue share remains below hospitals because complex and unstable patients require broader clinical support.

Academic and research institutes hold a 3.0% share, representing USD 30.0 million in 2025. Revenue is forecast to reach USD 43.9 million by 2032 at a CAGR of 5.6%. Direct purchasing is limited, but academic hospitals influence product adoption through physician training, procedural research and early evaluation of new drainage systems.

 

Geographic Segment Analysis

North America leads the market with an estimated 39.0% share in 2025, equal to USD 390.0 million. Revenue is projected to reach USD 598.1 million by 2032 at a CAGR of 6.3%. Mature interventional-radiology infrastructure, established reimbursement and high procedure access support regional leadership. Its global share is expected to decline as Asia Pacific expands faster.

Europe represents 28.0% of the market in 2025, or USD 280.0 million. Revenue is forecast to reach USD 426.6 million by 2032 at a CAGR of 6.2%. EUDAMED registration and traceability requirements increase the cost of maintaining extensive catheter and kit portfolios. Large manufacturers can spread those costs across broader product families, while smaller suppliers may reduce low-volume configurations.

Asia Pacific accounts for 24.0% of global revenue in 2025, equal to USD 240.0 million. The region is projected to reach USD 432.8 million by 2032 at a CAGR of 8.8%, the highest geographic growth rate. Expansion in interventional radiology, oncology services and image-guided urinary drainage is improving procedure conversion. Asia Pacific is expected to move slightly ahead of Europe by 2032.

Argon Medical’s 2026 expansion of its Singapore operations supports distributors across 20 Asia-Pacific countries. Local inventory and regional support improve tender participation and reduce delivery risk for emergency products. Similar investments will be necessary for suppliers seeking to convert the region’s disease burden into hospital sales.

Latin America represents 5.0% of 2025 revenue, equal to USD 50.0 million. The segment is projected to reach USD 80.3 million by 2032 at a CAGR of 7.0%. Growth is concentrated in private hospital networks and major urban referral centres. Uneven reimbursement and limited specialist coverage restrict wider adoption.

The Middle East and Africa account for 4.0% of the market, or USD 40.0 million in 2025. Revenue is forecast to reach USD 62.2 million by 2032 at a CAGR of 6.5%. Gulf hospital investment supports adoption, while limited imaging and interventional-radiology capacity constrain demand in less developed health systems.

 

Competition and Recent Market Developments

Boston Scientific, Cook Medical, Merit Medical Systems, Argon Medical Devices and Teleflex compete through combinations of catheters, access sets, guidewires, drainage systems, bags and fixation products. Portfolio breadth strengthens contract access because hospitals can standardize several procedure components under one supplier.

Cook Medical’s 2025 agreement with Vizient covers catheters, drainage devices, wire guides, balloons and ureteral stents. The contract places nephrostomy-related products inside a wider urology agreement and improves Cook’s access to large hospital purchasing networks.

Boston Scientific expanded its stone-management platform in 2026 with the FDA-cleared Asurys Fluid Management System for PCNL, ureteroscopy and cystoscopy. Cook Medical also introduced new suction-access and flexible-ureteroscopy products in 2026. Both developments strengthen supplier control over the wider stone-treatment budget rather than relying on nephrostomy catheters alone.

Teleflex agreed in December 2025 to sell its Acute Care and Interventional Urology businesses to Intersurgical for approximately USD 530 million. The transaction includes the broader urology operation associated with the Rüsch product family. Ownership transition creates a short-term opportunity for competitors to pursue affected hospital accounts, while Intersurgical gains a larger platform for bundled hospital-consumables contracts.

 

Market Outlook

The projected increase from USD 1.00 billion in 2025 to USD 1.60 billion by 2032 will be led by repeat exchanges, emergency drainage, cancer-related obstruction, outpatient intervention and wider interventional-radiology access.

Ureteral stents and tubeless PCNL will limit routine catheter placements. Higher revenue per chronic patient, growing use of accessories and continued demand for complete access kits will offset part of that pressure.

Suppliers with broad product portfolios, hospital contracts, reliable regional inventory and products covering initial access through long-term maintenance will capture more value than manufacturers competing mainly on catheter price.

 

Nephrostomy Devices Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.00 Billion
Revenue Forecast in 2032	USD 1.60 Billion
Overall Growth Rate	CAGR of 6.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Nephrostomy Catheters, Guidewires, Drainage Bags, Access Needles, Sheaths and Dilators, Other Products
By Application	Kidney Stones, Hydronephrosis, Kidney Cancer, Postoperative Urinary Diversion, Injury-Induced Obstruction
By End User	Hospitals, Ambulatory Surgical Centres, Specialty Clinics, Academic and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising incidence of complicated kidney-stone obstruction and hydronephrosis; repeated catheter exchanges and accessory replacement among long-term patients; increasing use of percutaneous renal access in oncology and stone-management procedures; expansion of interventional radiology and outpatient drainage services; growing demand for securement technologies that reduce accidental tube dislodgement and repeat interventions
Customization Option	Available upon request